US Dollar vs Yen

ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。

登録

ホーム
投資
株式
アメリカ
NASDAQ
Cocrystal Pharma Inc (COCP)
Cocrystal Pharma Inc (COCP) ニュース

COCP

Cocrystal Pharma (COCP)

Cocrystal Pharma Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:COCP

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/06/20	21 : 30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:COCP	Cocrystal Pharma Inc
2024/06/20	21 : 00	GlobeNewswire Inc.	New Broad-Spectrum Antiviral Currently in a Phase 2a Clinical Trial in Influenza A may be Effective Against the H5N1 Avian Influenza Strain Identified in Humans Exposed to Infected Dairy Cows	NASDAQ:COCP	Cocrystal Pharma Inc
2024/05/13	21 : 15	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:COCP	Cocrystal Pharma Inc
2024/05/13	21 : 00	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:COCP	Cocrystal Pharma Inc
2024/05/13	21 : 00	GlobeNewswire Inc.	Cocrystal Pharma Reports First Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs	NASDAQ:COCP	Cocrystal Pharma Inc
2024/05/08	05 : 30	Edgar (US Regulatory)	Form DEF 14A - Other definitive proxy statements	NASDAQ:COCP	Cocrystal Pharma Inc
2024/05/01	21 : 00	GlobeNewswire Inc.	Enrollment Completed in Phase 2a Study with Cocrystal Pharma’s Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal Influenza	NASDAQ:COCP	Cocrystal Pharma Inc
2024/03/28	21 : 00	GlobeNewswire Inc.	Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs	NASDAQ:COCP	Cocrystal Pharma Inc
2024/03/19	21 : 00	GlobeNewswire Inc.	Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A	NASDAQ:COCP	Cocrystal Pharma Inc
2024/03/02	06 : 15	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:COCP	Cocrystal Pharma Inc
2024/01/08	22 : 00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:COCP	Cocrystal Pharma Inc
2024/01/05	06 : 01	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:COCP	Cocrystal Pharma Inc
2024/01/04	22 : 00	GlobeNewswire Inc.	Cocrystal Pharma Provides an Update on the Clinical Development of its Novel, Broad-Spectrum Antiviral Investigational Candidates	NASDAQ:COCP	Cocrystal Pharma Inc
2024/01/02	23 : 53	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:COCP	Cocrystal Pharma Inc
2023/12/22	07 : 00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:COCP	Cocrystal Pharma Inc
2023/12/06	22 : 00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:COCP	Cocrystal Pharma Inc
2023/12/06	22 : 00	GlobeNewswire Inc.	Cocrystal Pharma Announces First-Patient-In for Phase 2a Human Challenge Study Evaluating Oral CC-42344 in Pandemic and Seasonal Influenza A	NASDAQ:COCP	Cocrystal Pharma Inc
2023/12/04	22 : 00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:COCP	Cocrystal Pharma Inc
2023/11/29	22 : 00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:COCP	Cocrystal Pharma Inc
2023/11/29	22 : 00	GlobeNewswire Inc.	Cocrystal Pharma Highlights its Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast	NASDAQ:COCP	Cocrystal Pharma Inc
2023/11/27	22 : 00	GlobeNewswire Inc.	Cocrystal Pharma to Present at the NobleCon 19 Conference on December 4, 2023	NASDAQ:COCP	Cocrystal Pharma Inc
2023/11/13	22 : 15	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:COCP	Cocrystal Pharma Inc
2023/11/13	22 : 01	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:COCP	Cocrystal Pharma Inc
2023/11/13	22 : 00	GlobeNewswire Inc.	Cocrystal Pharma Reports Third Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs	NASDAQ:COCP	Cocrystal Pharma Inc
2023/11/09	22 : 00	GlobeNewswire Inc.	Cocrystal Pharma to Discuss Progress with Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast	NASDAQ:COCP	Cocrystal Pharma Inc
2023/10/31	21 : 00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:COCP	Cocrystal Pharma Inc
2023/10/31	21 : 00	GlobeNewswire Inc.	Cocrystal Pharma Receives UK MHRA Authorization to Initiate Its Phase 2a Influenza Human Challenge Trial with Oral PB2 Inhibitor CC-42344	NASDAQ:COCP	Cocrystal Pharma Inc
2023/09/28	21 : 00	GlobeNewswire Inc.	Cocrystal Pharma Doses First Subjects in Clinical Study of CDI-988 For Pandemic Norovirus and Coronavirus	NASDAQ:COCP	Cocrystal Pharma Inc
2023/09/05	21 : 00	GlobeNewswire Inc.	Cocrystal Pharma to Participate in the H.C. Wainwright Global Investment Conference	NASDAQ:COCP	Cocrystal Pharma Inc
2023/08/17	05 : 05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:COCP	Cocrystal Pharma Inc

Showing the most relevant articles for your search:NASDAQ:COCP

1 2 3 4 5 6 7 8 9 10 次へ >>

Energy Select Sector SPDR

Verizon Communications

Invesco QQQ Trust Series 1

Health Care Select Sector

Financial Select Sector

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約